Following treatment with the β-blocker or docetaxel, no inhibition of p-Erk1/2/Erk1/2 was observed; instead, with the drug combination, the p-Erk1/2/Erk1/2 ratio was reduced by approximately 50% compared that in untreated cells (Fig. 6B,C), as shown by the significant inhibition of angiosarcoma cell proliferation. The gene discussed is MAPK3; the disease is angiosarcoma.